CY2404B1 - Use of rapamycin derivatives in vasculopathies andxenotransplantation. - Google Patents

Use of rapamycin derivatives in vasculopathies andxenotransplantation.

Info

Publication number
CY2404B1
CY2404B1 CY0400004A CY0400004A CY2404B1 CY 2404 B1 CY2404 B1 CY 2404B1 CY 0400004 A CY0400004 A CY 0400004A CY 0400004 A CY0400004 A CY 0400004A CY 2404 B1 CY2404 B1 CY 2404B1
Authority
CY
Cyprus
Prior art keywords
andxenotransplantation
vasculopathies
rapamycin derivatives
rapamycin
deoxyspergualine
Prior art date
Application number
CY0400004A
Other languages
English (en)
Inventor
Walter Schuler
Hendrik Schuurman
Gisbert Weckbecker
Hans-Guenter Zerwes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10791127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2404(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2404B1 publication Critical patent/CY2404B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY0400004A 1996-03-27 2004-01-08 Use of rapamycin derivatives in vasculopathies andxenotransplantation. CY2404B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9606452.2A GB9606452D0 (en) 1996-03-27 1996-03-27 Organic compounds

Publications (1)

Publication Number Publication Date
CY2404B1 true CY2404B1 (en) 2004-09-10

Family

ID=10791127

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0400004A CY2404B1 (en) 1996-03-27 2004-01-08 Use of rapamycin derivatives in vasculopathies andxenotransplantation.

Country Status (29)

Country Link
US (5) US6384046B1 (2)
EP (3) EP0893996B1 (2)
JP (2) JP2000507226A (2)
KR (2) KR100836971B1 (2)
CN (1) CN1124135C (2)
AT (1) ATE224194T1 (2)
AU (1) AU716514B2 (2)
BR (1) BR9708358A (2)
CA (1) CA2247275C (2)
CY (1) CY2404B1 (2)
CZ (1) CZ292483B6 (2)
DE (1) DE69715611T2 (2)
DK (2) DK0893996T3 (2)
ES (2) ES2184078T3 (2)
GB (1) GB9606452D0 (2)
HU (1) HU226422B1 (2)
ID (1) ID17195A (2)
IL (1) IL125812A (2)
MY (1) MY117798A (2)
NO (1) NO316667B1 (2)
NZ (1) NZ331463A (2)
PL (1) PL187732B1 (2)
PT (2) PT2008657E (2)
RU (1) RU2214247C2 (2)
SI (1) SI2008657T1 (2)
SK (1) SK284343B6 (2)
TR (1) TR199801919T2 (2)
WO (1) WO1997035575A1 (2)
ZA (1) ZA972719B (2)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
EP1208847B8 (en) 1996-07-30 2007-02-14 Novartis AG Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
JP2002544167A (ja) * 1999-05-10 2002-12-24 ノバルティス アクチエンゲゼルシャフト 有機化合物
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
ATE362382T1 (de) 2000-03-15 2007-06-15 Orbusneich Medical Inc Beschichtung welche ein anhaften von endothelzellen stimuliert
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
EP1709974A3 (en) * 2000-06-16 2006-12-06 Wyeth Method of treating cardiovascular disease using rapamycin
AU9486901A (en) 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
PL409579A1 (pl) * 2001-02-19 2015-03-02 Novartis Ag Leczenie raka
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US7682387B2 (en) * 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
CA2476832A1 (en) * 2002-02-22 2003-08-28 Prophy Med Ab Use of an inhibitor or antagonist against tissue factor
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
AU2003241515A1 (en) * 2002-05-20 2003-12-12 Orbus Medical Technologies Inc. Drug eluting implantable medical device
US8109987B2 (en) 2003-04-14 2012-02-07 Tryton Medical, Inc. Method of treating a lumenal bifurcation
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
EP2946666B1 (en) * 2004-04-30 2017-11-15 OrbusNeich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7901451B2 (en) * 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20060194829A1 (en) * 2004-12-20 2006-08-31 Clackson Timothy P Therapeutic materials and methods
CA2629714A1 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
CN101340859B (zh) * 2005-11-17 2010-12-15 路嘉株式会社 用于制备在对身体的医疗手术中使用的插入物的方法
US20070173923A1 (en) * 2006-01-20 2007-07-26 Savage Douglas R Drug reservoir stent
EP2083834B1 (en) 2006-09-13 2017-06-21 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080103584A1 (en) 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
US8661630B2 (en) 2008-05-21 2014-03-04 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
CA2705764C (en) 2007-11-14 2016-08-02 Biosensors International Group, Ltd. Automated stent coating apparatus and method
WO2009089549A1 (en) * 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
EP2352459A4 (en) * 2008-10-03 2013-09-25 Elixir Medical Corp MACROCYCLIC LACTON COMPOUNDS AND METHOD FOR THEIR USE
US8382818B2 (en) 2009-07-02 2013-02-26 Tryton Medical, Inc. Ostium support for treating vascular bifurcations
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
UA104738C2 (ru) 2011-05-18 2014-03-11 Олег Миколайович Лазаренко Композиция для повышения биосовместимости имплантатов и клеток для трансплантации с организмом реципиента и способ ее приготовления
CN102268015B (zh) * 2011-08-30 2013-08-28 成都摩尔生物医药有限公司 一种依维莫司的合成方法
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
CN105792775B (zh) 2013-09-24 2019-02-19 吉纳生命科学公司 用于细胞植入物的气体处理的系统
US10307370B2 (en) 2013-10-08 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
KR20160120739A (ko) 2014-02-11 2016-10-18 램 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
DK3125875T3 (da) 2014-04-04 2023-07-24 Ai Therapeutics Inc Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
KR20170095807A (ko) 2014-10-07 2017-08-23 램 테라퓨틱스, 인코포레이티드 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
WO2018031789A1 (en) 2016-08-10 2018-02-15 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
US12453624B2 (en) 2016-09-19 2025-10-28 Biotronik Ag Polymer-free drug eluting vascular stents
MX2019005676A (es) 2016-11-15 2019-09-10 Giner Life Sciences Inc Dispositivo percutáneo de difusión de gases adecuado para su uso con un implante subcutáneo.
CN109996569B (zh) 2016-12-22 2022-05-03 百多力股份公司 用于医疗装置的药物释放涂层及其制备方法
JP7199632B2 (ja) 2017-05-04 2023-01-06 ガイナー,インク. 堅牢なインプラント可能なガス送達装置ならびにそれを含む方法、システムおよび装置
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
MX2021007247A (es) 2018-12-18 2021-07-15 Novartis Ag Derivados de rapamicina.
BR112021016296A2 (pt) 2019-02-20 2021-11-09 Ai Therapeutics Inc Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2094858C (en) * 1992-04-28 2004-06-15 Robert D. Mitchell Method of treating hyperproliferative vascular disease
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5912253A (en) * 1993-12-17 1999-06-15 Novartis Ag Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
EP0833828B1 (en) * 1995-06-09 2002-11-20 Novartis AG Rapamycin derivatives
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
GB9606452D0 (en) 1996-06-05
PL328659A1 (en) 1999-02-15
MY117798A (en) 2004-08-30
JP2000507226A (ja) 2000-06-13
US20140187574A1 (en) 2014-07-03
CZ307098A3 (cs) 1999-01-13
EP0893996B1 (en) 2002-09-18
ES2184078T3 (es) 2003-04-01
KR100836971B1 (ko) 2008-06-10
EP2008657B1 (en) 2013-04-24
US20120177690A1 (en) 2012-07-12
HK1018688A1 (en) 1999-12-30
IL125812A (en) 2001-12-23
KR20050038656A (ko) 2005-04-27
DE69715611D1 (de) 2002-10-24
HUP0001267A2 (hu) 2000-11-28
ZA972719B (en) 1998-09-28
BR9708358A (pt) 1999-08-03
ES2421455T3 (es) 2013-09-02
IL125812A0 (en) 1999-04-11
JP2009102349A (ja) 2009-05-14
NO984340D0 (no) 1998-09-18
HU226422B1 (en) 2008-12-29
US6384046B1 (en) 2002-05-07
CA2247275A1 (en) 1997-10-02
CZ292483B6 (cs) 2003-09-17
US20020127248A1 (en) 2002-09-12
SK284343B6 (sk) 2005-02-04
CN1124135C (zh) 2003-10-15
SK132798A3 (en) 1999-03-12
DK2008657T3 (da) 2013-07-22
EP0893996A1 (en) 1999-02-03
AU716514B2 (en) 2000-02-24
CN1214631A (zh) 1999-04-21
EP2008657A2 (en) 2008-12-31
DK0893996T3 (da) 2002-12-09
NO316667B1 (no) 2004-03-29
NO984340L (no) 1998-09-18
EP1149581A2 (en) 2001-10-31
AU2291897A (en) 1997-10-17
PT2008657E (pt) 2013-07-12
SI2008657T1 (sl) 2013-07-31
EP1149581A3 (en) 2003-12-03
CA2247275C (en) 2011-10-11
DE69715611T2 (de) 2003-05-22
HUP0001267A3 (en) 2002-01-28
NZ331463A (en) 2001-10-26
TR199801919T2 (xx) 1999-02-22
ATE224194T1 (de) 2002-10-15
ID17195A (id) 1997-12-11
KR20070083654A (ko) 2007-08-24
PT893996E (pt) 2002-12-31
PL187732B1 (pl) 2004-09-30
WO1997035575A1 (en) 1997-10-02
RU2214247C2 (ru) 2003-10-20
US20100152105A1 (en) 2010-06-17
JP5124431B2 (ja) 2013-01-23
EP2008657A3 (en) 2009-02-04

Similar Documents

Publication Publication Date Title
ZA972719B (en) Use of rapamycin derivatives in vasculopathies and xenotransplantations
IL140137A (en) Receptor bodies specifically binding tie-2 ligands
TW249198B (en) Stents for autologous tissue heart valve
DE69205845D1 (de) Katalysatorträger, zusammensetzung und Verfahren zu seiner Herstellung.
ZA951292B (en) 4-amino derivatives of mycophenolic acid
ES2054627T3 (es) Indolinas 3,3-disustituidas.
ES2184800T3 (es) Uso de agentes anti-vegf en el tratamiento de la endometriosis.
WO2003101919A3 (en) Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same
DE69112007D1 (de) Ferritischer, hitzebeständiger Gussstahl und Verfahren zu seiner Herstellung.
RU98101907A (ru) Терапевтические агенты и аутоимунные заболевания
DE602004017838D1 (de) Verfahren zur herstellung von 6-ä(4,5-dihydro-1h-imidazol-2-yl)amino-ü-7-methyl-1h-benzimidazol-4-carbonitrile und dessen bevorzugte salzform
DK0745071T3 (da) 4-Amino-6-substitueret mycophenolsyre og derivater med immunsuppressiv virkning
MX9603484A (es) Derivados de 4-amino de acido micofenolico 5-sustituido.
RU2000124058A (ru) Способ лечения миопии
RU96119633A (ru) Способ лечения аметропий и разницы в функциональных показателях правого и левого глаза по святковской т.я.
Dao Common pronunciation mistakes among second-year English-major Students at Thuongmai University: causes and strategies for improvement
Pioli Reactivation failure in infants: A processing analysis.
IT1241270B (it) Procedimento per realizzare vaschette di contenimento per cuscini, particolarmente cuscini di sedili per autoveicoli.
UA36539A (uk) Спосіб проведення тренувань, що засновані на переміщеннях пацієнта, та комплекс засобів для його здійснення
ES1022409U (es) Soporte para ceniceros, posavasos y similares desechables o no desechables.